| Release Date: January 2008 | Valid Through: December 31, 2008 |
Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)TM
|
| Fee: There is no fee for this activity. |
| Target Audience: This CME activity is designed for oncology professionals who treat breast cancer patients. |
This CME activity is based on the following:
Bone Loss and Bone Metastases in Breast Cancer: A Report from the 2007 San Antonio Breast Cancer Symposium (SABCS)
Georgiana Ellis, MD, Associate Professor, Medical Oncology Division at the University of Washington School of Medicine, Seattle, Washington
Please read the following CME information for this activity and then select the link below to launch the activity.
Georgiana Ellis, MD
Dr. Georgiana K. Ellis is an Associate Professor in the Medical Oncology Division at the University of Washington School of Medicine and an Oncology Specialist at the Seattle Cancer Care Alliance. Dr. Ellis received her medical degree from the University of Washington, Seattle, Washington and completed her Internal Medicine Residency and was a Post-Doctoral Fellow in Oncology at the University of Washington, Seattle, Washington. Her clinical interests are in breast cancer-multidisciplinary care, dose intrinsity in cancer chemotherapy, and maximizing breast cancer cures.
Learning Objectives
In general, oncology/hematology professionals who avail themselves of the SABCS 2007 bone health conference summary should be able to:
- Evaluate breast cancer bone metastases and bone loss clinical trial data presented at SABCS based on study design, the reported results, and authors’ conclusions.
- Consider the reviewed data as it relates to previous, concurrent and future treatment of breast cancer bone issues with bisphosphonates.
- Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer.
- Evaluate the clinical usefulness of bisphosphonates in oncology: treatment of bone metastases, antitumoral activity and effect on bone resorption markers.
- Effect of bisphosphonates on bone loss in women undergoing chemotherapy for breast cancer.
Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Creative Educational Concepts, Inc. (CEC) and OncoEd, Inc. CEC is accredited by the ACCME to provide continuing medical education for physicians. CEC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. CEC is an equal opportunity/affirmative action institution. | Instructions for Participation This activity was released January 2008 and will be valid through December 31, 2008. There are no fees for participating and receiving credit for this activity. To successfully complete this activity, participants must do the following: - Read the target audience, learning objectives, and author disclosures.
- Study the educational activity online or printed out.
- Read, complete, and submit answers to the post test questions and evaluation questions online and click "submit" when finished.
- After clicking "submit," your online certificate will be made available for you to view and print.
Hardware/Software Requirements This website requires version 4.x browsers or higher from Microsoft or Netscape. It has been optimized for Microsoft Browsers. |
Supporters
This activity is supported by an educational grant provided by Novartis and an educational donation provided by Amgen.
Faculty and Disclosures
CEC is committed to the provision of CME that is balanced, objective, and evidence based. CEC adheres to Accreditation Council for Continuing Medical Education (ACCME) Essentials and Standards. Accordingly, all parties involved in content development have disclosed any real or apparent conflicts of interest relating to the topics of this educational activity and the disclosure summary follows. CEC has established mechanisms to resolve conflicts of interest should they arise. Participants in CEC CME programs are afforded the opportunity to provide feedback on the quality of individual programs.
Author: Georgiana Ellis, MD
Disclosure: Dr. Ellis has disclosed that she has received research/grant support from Amgen and Roche, has been on the Speaker's Bureau for Novartis and has participated in advisory boards for Amgen, Novartis, Astra Zeneca, Abraxis and Genomic Health.
Editor: C. Dean Buckner, MD, OncoEd, Inc.
Disclosure: Dr. Buckner has no relevant financial interests to disclose.
Interviewer: Kari Bohlke, ScD, OncoEd, Inc.
Disclosure: Dr. Bohlke has no relevant financial interests to disclose.
Investigational and/or off-label use of commercial products and devices
CEC requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
The presentations in this CME activity might include discussion of investigational and/or unlabeled use of drugs. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.
Privacy and Confidentiality
OncoEd is committed to respecting your privacy. We've structured our web site so that you can visit OncoEd on the web without identifying yourself or revealing any personal information. If you choose to provide us personally identifiable information, you can be assured that it will only be used to support your relationship with OncoEd.
On some OncoEd web pages, you can make requests, and register to receive materials. The types of personal information collected at these pages are name and contact information. In order to tailor our subsequent communications to you and continuously improve our products and services, we may also ask you to voluntarily provide us with information regarding your experience with cancer, personal or professional interests, demographics and contact preferences.
OncoEd is committed to ensuring the security of your information. To prevent unauthorized access, maintain data accuracy, and ensure the appropriate use of information, we have put in place appropriate physical, electronic, and managerial procedures to safeguard and secure the information we collect online.
OncoEd has links to many other sites and cannot ensure the privacy or security of information you provide to the linked site.
If you have comments or questions about our privacy policy, please send them to this email address: mail@onco-ed.com.
Disclaimer
Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC.
I have read the required CME information.
Yes: Click Here to Launch the Activity
No: Click Here to Return to the Homepage
Patient Home
